EVEREST STUDY: Efficacy and Safety of Verteporfin Photodynamic Therapy in Combination with Ranibizumab or Alone Versus Ranibizumab Monotherapy in Patients with Symptomatic Macular Polypoidal Choroidal Vasculopathy
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
In Brief Purpose: To assess the effects of verteporfin photodynamic therapy (PDT) combined with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Methods: In this multicenter, double-masked, primarily indocyanine green angiography–guided trial, 61 Asian patients were randomized to verteporfin PDT (standard fluence), ranibizumab 0.5 mg, or the combination. Patients were administered with verteporfin PDT/placebo and initiated with three consecutive monthly ranibizumab/sham injections starting Day 1, and re-treated (Months 3–5) as per predefined criteria. The primary endpoint was the proportion of patients with indocyanine green angiography–assessed complete regression of polyps at Month 6. Secondary endpoints included mean change in best-corrected visual acuity at Month 6 and safety. Results: At Month 6, verteporfin combined with ranibizumab or alone was superior to ranibizumab monotherapy in achieving complete polyp regression (77.8% and 71.4% vs. 28.6%; P < 0.01); mean change ± standard deviation in best-corrected visual acuity (letters) was 10.9 ± 10.9 (verteporfin PDT + ranibizumab), 7.5 ± 10.6 (verteporfin PDT), and 9.2 ± 12.4 (ranibizumab). There were no new safety findings with either drug used alone or in combination. Conclusion: Verteporfin PDT combined with ranibizumab 0.5 mg or alone was superior to ranibizumab monotherapy in achieving complete regression of polyps in this 6-month study in patients with symptomatic macular polypoidal choroidal vasculopathy. All treatments were well tolerated over 6 months. EVEREST, the first, multicenter, double-masked, primarily indocyanine green angiography–guided randomized controlled trial for symptomatic macular polypoidal choroidal vasculopathy, demonstrated superiority of verteporfin photodynamic therapy combined with ranibizumab or alone over ranibizumab monotherapy in achieving complete regression of polyps at Month 6. Best-corrected visual acuity improved in all treatment arms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the United Kingdom, ICGA is not available in all units and is usually reserved for cases presenting with clinical features suspicious of polypoidal choroidopathy (IPCV) or retinal angiomatous proliferation (RAP) or when response to anti-VEGF therapy is suboptimal.11,12”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
In the citing paper
“Some lesion types are thought to be less responsive than others to anti-VEGF therapy, for example, IPCV.”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
In the citing paper
“The EVEREST study suggested that combination therapy of IPCV with photodynamic therapy (PDT) and ranibizumab led to a better outcome than monotherapy with ranibizumab.11,12”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
In the citing paper
“However, an expanding or increased elevation in PED indicates activity that merits evaluation and treatment.11,12”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
Citations
Cites
Chung, S. E., Kang, S. W., Lee, J. H., & Kim, Y. T. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.09.012 · Cited by 580
Polypoidal Choroidal Vasculopathy: Incidence, Demographic Features, and Clinical Characteristics
Sho, K. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.10.1392 · Cited by 439 · cited 1×
“Moreover, the incidence of sub-RPE hemorrhage or subretinal hemorrhage in patients with PCV is high (30%–64%).(3,9) In a study of the natural history of patients with PCV, Uyama et al(6) reported that half of the study eyes had hemorrhagic episodes, recurrent leakage, or severe RPE atrophy after a long follow-up perio…”
BackgroundThe Expanding Clinical Spectrum of Idiopathic Polypoidal Choroidal Vasculopathy
Yannuzzi, L. A. (1997) · Archives of Ophthalmology · doi:10.1001/archopht.1997.01100150480005 · Cited by 436 · cited 3×
“It may be associated with a branching vascular network (BVN) and clinically visible orange-red subretinal nodule(s).(1) Polypoidal choroidal vasculopathy is prevalent in 10% to 54% of the Asian patients and in 8% to 12% of white patients with presumed exudative age-related macular degeneration (AMD).”
BackgroundPolypoidal choroidal vasculopathy: natural history
Uyama, M., Wada, M., Nagai, Y., Matsubara, T., Matsunaga, H., Fukushima, I., Takahashi, K., & Matsumura, M. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01404-6 · Cited by 402 · cited 3×
“In PCV, the polypoidal lesions originate from the inner choroidal vasculature and can progress beneath the RPE.(1,6,7) The presence of orange-red nodule–like structures beneath the RPE associated with an adjacent serous pigment epithelial detachment or overlying neurosensory detachment, subretinal hemorrhage, and lipi…”
BackgroundTong, J.-P., Chan, W.-M., Liu, D. T. L., Lai, T. Y. Y., Choy, K.-W., Pang, C.-P., & Lam, D. S. C. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.10.012 · Cited by 385 · cited 1×
“The increased expression of VEGF in the aqueous humor of eyes with PCV provides a biologic rationale for treatment with anti-VEGF agents.(19) Limited data from case series with bevacizumab monotherapy have shown that treatment may reduce leakage associated with PCV but is ineffective for complete regression of the pol…”
BackgroundSelf-citationPhotodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy
Chan, W.-M., Lam, D. S. C., Lai, T. Y. Y., Liu, D. T. L., Li, K. K. W., Yao, Y., & Wong, T.-H. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2003.12.056 · Cited by 283
Self-citation(2003) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(03)00223-x · Cited by 274 · cited 1×
“For CNV secondary to AMD, the Verteporfin In Photodynamic Therapy and the Treatment of AMD with Photodynamic Therapy study has demonstrated that there was gradual visual deterioration or no visual improvement with high re-treatment rate at 6 months for treated patients after verteporfin PDT administration.(25) This tr…”
ResultEfficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy
Gomi, F., Sawa, M., Sakaguchi, H., Tsujikawa, M., Oshima, Y., Kamei, M., & Tano, Y. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.122283 · Cited by 242 · cited 1×
“These findings are consistent with those reported earlier with other anti-VEGF therapies.(20,21)”
ResultGomi, F., Ohji, M., Sayanagi, K., Sawa, M., Sakaguchi, H., Oshima, Y., Ikuno, Y., & Tano, Y. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.02.031 · Cited by 239
The origins of polypoidal choroidal vasculopathy
Yuzawa, M. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2004.049296 · Cited by 198 · cited 4×
“Use of dynamic confocal scanning laser ophthalmoscope–ICGA may assist in further elucidating the BVN, from which these focal evaginating nodules arise, enabling clearer definition and differentiation from exudative AMD because of CNV.(7) Based on ICGA findings, PCV is defined as the presence of single or multiple foca…”
BackgroundInfluential
Cited by
Items 101–200 of 586
Ziemssen, F., & Heimann, H. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.701617 · Cited by 41
Ruamviboonsuk, P., Ng, D. S., Chaikitmongkol, V., Chang, A., Chen, S., Chen, Y., Cheung, C. M. G., Gomi, F., Guymer, R. H., Kim, J. E., et al. (2025) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2025.100144 · Cited by 42
Self-citationSaito, M., Iida, T., Kano, M., & Itagaki, K. (2013) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-013-2323-6 · Cited by 38
“The EVEREST study is the first double-masked randomized controlled trial to evaluate if PDT plus ranibizumab or PDT monotherapy is superior to ranibizumab monotherapy for achieving complete regression of polypoidal lesions (primary outcome) with 6-month follow-up [30].”
BackgroundMatsumiya, W., Honda, S., Kusuhara, S., Tsukahara, Y., & Negi, A. (2013) · BMC Ophthalmology · doi:10.1186/1471-2415-13-10 · Cited by 39
Cheung, C. M. G., Laude, A., Wong, W., Mathur, R., Chan, C. M., Wong, E. Y., Wong, D., Wong, T. Y., & Lim, T. H. (2015) · Retina · doi:10.1097/iae.0000000000000482 · Cited by 40
“Recently, a set of criteria was used in the first randomized-controlled trial on PCV (EVEREST trial), based on central reading center grading using confocal scanning laser ophthalmoscope–based ICGA.(15) The EVEREST criteria for PCV diagnosis was made with the presence of subretinal focal hyperfluorescence on ICGA with…”
BackgroundMethodInfluentialSelf-citationPolypoidal choroidal vasculopathy: a comprehensive clinical update
Kumar, A., Kumawat, D., Sundar, M., Gagrani, M., Gupta, B., Roop, P., Hasan, N., Sharma, A., & Chawla, R. (2019) · Therapeutic Advances in Ophthalmology · doi:10.1177/2515841419831152 · Cited by 41
Lai, T. Y. Y., Wong, R. L. M., & Chan, W. (2015) · Europe PMC (PubMed Central) · Cited by 48
Self-citationShin, J. Y., Kwon, K. Y., & Byeon, S. H. (2015) · Acta Ophthalmologica · doi:10.1111/aos.12653 · Cited by 37
“PDT has been suggested to be superior to ranibizumab monotherapy in achieving complete polyp regression (Koh et al. 2012).”
BackgroundAsian Age-Related Macular Degeneration: Current Concepts and Gaps in Knowledge
Lim, L. S., Cheung, C. M. G., & Wong, T. Y. (2013) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0b013e31827ff5bc · Cited by 39
“The EVEREST study was a multicenter, doublemasked, primarily ICGA-guided trial comparing standard fluence PDT, ranibizumab, or a combination thereof.(119) Sixty-one subjects were enrolled and followed up for 6 months.”
MethodTreat-and-Extend Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration
Matsumoto, H., Morimoto, M., Mimura, K., Ito, A., & Akiyama, H. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.09.002 · Cited by 37
Ijiri, S., & Sugiyama, K. (2014) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-014-2707-2 · Cited by 37
“Gomi [11] Hikichi [8] Koizumi [9] Koh [10] Present study”
BackgroundInfluentialInoue, M., Arakawa, A., Yamane, S., & Kadonosono, K. (2013) · Eye · doi:10.1038/eye.2013.179 · Cited by 36
Waldstein, S. M., Ritter, M., Simader, C., Sponer, U., Kundi, M., & Schmidt-Erfurth, U. M. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.04.028 · Cited by 36
Kokame, G. T., Lai, J. C., Wee, R., Yanagihara, R. T., Shantha, J. G., Ayabe, J., & Hirai, K. (2016) · BMC Ophthalmology · doi:10.1186/s12886-016-0305-2 · Cited by 38
Demirel, S., Yanık, Ö., Nalcı, H., Batıoğlu, F., & Özmert, E. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3793-8 · Cited by 35
“Photodynamic therapy for PCV, the last of these spectrum diseases, should also be combined with an anti-VEGF agent [20].”
BackgroundHata, M., Tagawa, M., Oishi, A., Kawashima, Y., Nakata, I., Akagi-Kurashige, Y., Yamashiro, K., Ooto, S., Tamura, H., Miyata, M., et al. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.06.013 · Cited by 36
Alshahrani, S., Shamsi, H. A., Kahtani, E. A., & Ghazi, N. G. (2014) · Clinical ophthalmology · doi:10.2147/opth.s68471 · Cited by 36
Characteristics of Neovascular Age-Related Macular Degeneration in Brazilian Patients
Pereira, F. B., Veloso, C. E. D. R., Kokame, G. T., & Nehemy, M. B. (2015) · Ophthalmologica · doi:10.1159/000439359 · Cited by 33
ONE-YEAR RESULTS OF INTRAVITREAL AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY
Hara, C., Sawa, M., Sayanagi, K., & Nishida, K. (2015) · Retina · doi:10.1097/iae.0000000000000767 · Cited by 36
Sakurada, Y., Sugiyama, A., Tanabe, N., Kikushima, W., Kume, A., & Iijima, H. (2016) · Retina · doi:10.1097/iae.0000000000001427 · Cited by 34
Souied, E. H., Addou-Regnard, M., Ohayon, A., Semoun, O., Querques, G., Blanco-Garavito, R., Bunod, R., Jung, C., Sikorav, A., & Mière, A. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.02.016 · Cited by 35
Kim, K., Yang, J. Y., Feuer, W. J., Gregori, G., Kim, E. S., Rosenfeld, P. J., & Yu, S. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.05.017 · Cited by 36
Combination therapy for the treatment of neovascular age-related macular degeneration
Englander, M., & Kaiser, P. K. (2013) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32835f8eaa · Cited by 33
AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: As Needed Versus Fixed Interval Dosing
Inoue, M., Yamane, S., Taoka, R., Arakawa, A., & Kadonosono, K. (2015) · Retina · doi:10.1097/iae.0000000000000933 · Cited by 33
on behalf of the EVEREST Study Group, Tan, C. S., Ngo, W. K., Lim, L. W., Tan, N., & Lim, T. H. (2016) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-016-3333-y · Cited by 32
“The EVERESTstudy [18] reported a higher rate of polyp closure among patients treated with PDT combined with intravitreal ranibizumab (Novartis AG, Basel, Switzerland) or with PDT monotherapy compared to the group treated with ranibizumab monotherapy.”
MethodInfluentialSelf-citationHosokawa, M. M., Morizane, Y., Hirano, M., Kimura, S., Kumase, F., Shiode, Y., Doi, S., Toshima, S., Hosogi, M., Fujiwara, A., et al. (2016) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-016-0492-7 · Cited by 32
“Although previous studies have reported that PDT is more effective than anti-VEGF drugs, such as ranibizumab, for causing regression of the polypoidal lesions, the visual outcomes were reportedly better in patients who received anti-VEGF therapy than in those who received PDT [2, 6].”
BackgroundInfluentialTeo, K. Y. C., Gillies, M. C., & Fraser‐Bell, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092611 · Cited by 32
“5 letters), although the difference was not statistically significant and the study was not powered to examine vision change as the primary outcome [36].”
BackgroundFujita, A., Kataoka, K., Takeuchi, J., Nakano, Y., Horiguchi, E., Kaneko, H., Ito, Y., & Terasaki, H. (2020) · Retina · doi:10.1097/iae.0000000000002760 · Cited by 32
Bo, Q., Zhang, M., Chen, J., Jia, H., Shen, M., Sun, M., Xu, M., Feng, J., Yan, Q., Yang, Y., et al. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.09.013 · Cited by 31
Hata, M., Tsujikawa, A., Miyake, M., Yamashiro, K., Ooto, S., Oishi, A., Nakanishi, H., Takahashi, A., & Yoshimura, N. (2014) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-014-2688-1 · Cited by 33
Kang, H. M., Koh, H. J., Lee, C. S., & Lee, S. C. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.11.015 · Cited by 32
Lee, M. Y., Lee, W. K., Baek, J., Kwon, O. W., & Lee, J. H. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.04.001 · Cited by 31
Self-citationCurrent choice of treatments for neovascular AMD
Lai, K. E., & Landa, G. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.990379 · Cited by 33
“Though VPDT has largely become obsolete, combined VPDT with ranibizumab is still used in PCV which may result in a higher rate of polyp closure [18].”
BackgroundHosokawa, M. M., Shiraga, F., Yamashita, A., Shiragami, C., Ono, A., Shirakata, Y., Kimura, S., Shiode, Y., Kawata, T., Hosogi, M., et al. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305275 · Cited by 32
Kokame, G. T. (2014) · Europe PMC (PubMed Central) · Cited by 32
Hikichi, T. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2017-310448 · Cited by 30
Reibaldi, M., Fallico, M., Avitabile, T., Bonfiglio, V. M. E., Russo, A., Castellino, N., Parisi, G., Longo, A., Pulvirenti, A., Boscia, F., et al. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.4636 · Cited by 33
Submacular Hemorrhage: Visual Outcomes and Prognostic Factors
Kunavisarut, P., Thithuan, T., Patikulsila, D., Choovuthayakorn, J., Watanachai, N., Chaikitmongkol, V., Pathanapitoon, K., & Rothová, A. (2017) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.2017389 · Cited by 37
van Dijk, E. H. C., Mohabati, D., Veselinovic, S., Chung, W., Dijkman, G., & Boon, C. J. F. (2020) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-020-04844-z · Cited by 30
Teo, K. Y. C., Sadda, S. R., Cheung, C. M. G., Chakravarthy, U., Staurenghi, G., Invernizzi, A., Ogura, Y., Ruamviboonsuk, P., Chen, S., Gupta, V., et al. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2021.04.002 · Cited by 29
Self-citationCheung, C. M. G. (2023) · Eye · doi:10.1038/s41433-023-02764-w · Cited by 34
“The EVEREST study compared PDT alone, PDT combined with intravitreal ranibizumab (IVR), and IVR mono-therapy in 60 participants in a randomized design over 6 months, and reported higher polyp closure (77.8% and 71.4% versus 28.6%, p 0.01) in the two PDT treatment arms compared to IVR alone [42].”
ResultInfluentialTreatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept
García‐Layana, A., Figueroa, M. S., Araiz, J., Ruiz‐Moreno, J. M., Gómez‐Ulla, F., Arias, L., & Reiter, N. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0300-y · Cited by 31
“The EVEREST study [78] was the first exploratory randomized controlled trial evaluating standard fluence PDT with or without ranibizumab 0.”
MethodChaikitmongkol, V., Khunsongkiet, P., Patikulsila, D., Ratanasukon, M., Watanachai, N., Jumroendararasame, C., Mayerle, C. B., Han, I. C., Chen, C. J., Winaikosol, P., et al. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.05.005 · Cited by 37
POLYPOIDAL CHOROIDAL VASCULOPATHY IN WHITE PATIENTS
Davis, S. J., Lauer, A. K., & Flaxel, C. J. (2014) · Retina · doi:10.1097/iae.0000000000000206 · Cited by 30
Teo, K. Y. C., Yanagi, Y., Lee, S. Y., Yeo, I. Y. S., Tan, G. S. W., Mathur, R., Chan, C. M., Wong, T. Y., & Cheung, C. M. G. (2017) · Retina · doi:10.1097/iae.0000000000001776 · Cited by 28
Miyata, M., Ooto, S., Yamashiro, K., Tamura, H., Hata, M., Ueda‐Arakawa, N., Yoshikawa, M., Numa, S., & Tsujikawa, A. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-311963 · Cited by 30
Siedlecki, J., Klaas, J. E., Keidel, L. F., Asani, B., Luft, N., Priglinger, S. G., & Schworm, B. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.04.004 · Cited by 28
Gupta, V., Agarwal, A. K., & Aggarwal, K. (2016) · Middle East African Journal of Ophthalmology · doi:10.4103/0974-9233.173133 · Cited by 29
Nesper, P. L., Soetikno, B. T., Treister, A. D., & Fawzi, A. A. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-23361 · Cited by 28
“Polypoidal choroidal vasculopathy was diagnosed based on the presence of a shallow PED on OCT with ‘‘double layer sign’’ confirmed as a branching vascular network on indocyanine green angiography (ICGA) along with a peaked PED on OCT confirmed as polyps on ICGA.(28,29) We included eyes treated with ranibizumab, bevaci…”
BackgroundShin, Y., Sung, J.-Y., Sagong, M., Lee, Y. H., Jo, Y. J., & Kim, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-28938-1 · Cited by 28
Polypoidal Choroidal Vasculopathy—An Important Diagnosis to Make with Therapeutic Implications
Kokame, G. T. (2012) · Retina · doi:10.1097/iae.0b013e3182695bf8 · Cited by 27
Miyamoto, N., Mandai, M., Oishi, A., Nakai, S., Honda, S., Hirashima, T., Oh, H., Matsumoto, Y., Uenishi, M., & Kurimoto, Y. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-312419 · Cited by 28
Current management strategy of polypoidal choroidal vasculopathy
Lai, T. Y. Y., & Ho, C. P. S. (2018) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_975_18 · Cited by 28
“However, half‑dose vPDT was superior than standard‑dose vPDT when baseline BCVA was 20/50 or better, or when there were three or less polyps on the baseline ICGA.”
MethodResultInfluentialSelf-citationMiki, A., Honda, S., Kondo, N., & Negi, A. (2013) · Ophthalmic Genetics · doi:10.3109/13816810.2012.749288 · Cited by 26
“It is well documented that branching vascular networks remain in most PCV cases although polypoidal lesions disappear after PDT, and they often cause new polypoidal lesions at the edge of the branching vascular networks.(23,24) We hypothesized that the ARMS2 A69S variant may contribute to the formation of branching ne…”
BackgroundSHORT-TERM EFFICACY OF CONBERCEPT AND RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY
Huang, Z., Ding, Q., Yan, M., Lian, H., Chen, Z., Chen, X., & Song, Y. (2018) · Retina · doi:10.1097/iae.0000000000002035 · Cited by 27
Tan, C. S., Lim, L. W., Ngo, W. K., Lim, T. H., & for the EVEREST Study Group (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22683 · Cited by 26
“The study design, treatment protocols, and overall clinical outcomes have previously been described in detail.(14) In brief, 61 patients diagnosed with symptomatic macular PCV were randomized equally into one of three treatment arms: (1) PDT with verteporfin (Visudyne; Novartis International AG, Basel, Switzerland) co…”
BackgroundMethodSelf-citationMori, R., Yuzawa, M., Akaza, E., & Haruyama, M. (2013) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-013-0245-9 · Cited by 25
“In the EVEREST study [8], complete Fig.”
Backgroundvan Dijk, E. H. C., Holtz, J. K., Sirks, M. J., Larsson, J., Diederen, R. M. H., Schlingemann, R. O., Boon, C. J. F., & Subhi, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164766 · Cited by 33
Current Choroidal Neovascularization Treatment
Liu, J., Ye, P., & Wen, X. (2013) · Ophthalmologica · doi:10.1159/000351660 · Cited by 29
Optical Coherence Tomography-based Diagnosis of Polypoidal Choroidal Vasculopathy in Korean Patients
Chang, Y. S., Kim, J. H., Kim, J. W., Lee, T. G., & Kim, C. G. (2016) · Korean Journal of Ophthalmology · doi:10.3341/kjo.2016.30.3.198 · Cited by 25
“Thus, the choroidal thickness criteria suggested in the present study may not be valid for detecting these PCVs with a thin choroid.”
BackgroundInfluentialKimura, S., Morizane, Y., Hosokawa, M. M., Shiode, Y., Doi, S., Hosogi, M., Fujiwara, A., Okanouchi, T., Inoue, Y., & Shiraga, F. (2019) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-019-00679-2 · Cited by 24
Characteristics of pachychoroid neovasculopathy
Tagawa, M., Ooto, S., Yamashiro, K., Tamura, H., Oishi, A., Miyata, M., Hata, M., Yoshikawa, M., Yoshimura, N., & Tsujikawa, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-73303-w · Cited by 25
Yamashiro, K., Oishi, A., Hata, M., Takahashi, A., & Tsujikawa, A. (2021) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-021-00869-x · Cited by 24
Perspectives and Update on the Global Shortage of Verteporfin (Visudyne®)
Sirks, M. J., Subhi, Y., Rosenberg, N., Hollak, C., Boon, C., Diederen, R., Yzer, S., Norel, J. O.-V., de Jong-Hesse, Y., Schlingemann, R., et al. (2024) · Ophthalmology and Therapy · doi:10.1007/s40123-024-00952-9 · Cited by 23
Yong, M. H., Zhou, M., & Deng, G. (2015) · BMC Ophthalmology · doi:10.1186/s12886-015-0064-5 · Cited by 24
“On the other hand, anti-VEGF treatment has its own inherent merits of reducing exudative lesions, leakage, resolving fluids, and improving VA, but it is ineffective for polyp regression [7, 21].”
BackgroundTang, K., Si, J.-K., Guo, D., Cui, Y. R., Du, Y., Pan, X., & Bi, H.-S. (2015) · Europe PMC (PubMed Central) · doi:10.3980/j.issn.2222-3959.2015.05.36 · Cited by 24
Wang, Y., Yang, J., Li, B., Yuan, M., & Chen, Y. (2019) · Journal of Ophthalmology · doi:10.1155/2019/6837601 · Cited by 24
“According to the EVEREST study [5], focal hyperfluorescent lesions appearing before 6 minutes on ICGA are necessary for the diagnosis of PCV.”
MethodJu, Y., Dai, X., Tang, Z., Ming, Z., Ni, N., Zhu, D., Zhang, J., Ma, B., Wang, J., Huang, R., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.01.028 · Cited by 28
Ueda‐Consolvo, T., Tanigichi, A., Numata, A., Oiwake, T., Nakamura, T., Ishida, M., Yanagisawa, S., & Hayashi, A. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05793-5 · Cited by 27
Kuo, J. Z.-C., Wong, T. Y., & Ong, F. S.-C. (2013) · Expert Review of Ophthalmology · doi:10.1586/eop.13.3 · Cited by 30
Lorentzen, T. D., Subhi, Y., & Sørensen, T. L. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13646 · Cited by 25
“Considering that the best treatment option and strategy for PCV may differ from those of the exudative AMD (Koh et al. 2012; Sakai et al. 2016), refraining from using ICGA as a routine may lead to suboptimal treatment of the patients.”
BackgroundCurrent and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis
Todorich, B., Yiu, G. C., & Hahn, P. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.890047 · Cited by 24
“However, with increased use of more efficacious anti-VEGF therapy for neovascular AMD, the use of PDT has fallen out of favor and is employed today mainly in combination with antiVEGF therapy for treatment-resistant cases of subfoveal CNV or for AMD variants such as idiopathic polypoidal choroidal vasculopathy, which…”
BackgroundSato, T., Kishi, S., Matsumoto, H., & Mukai, R. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.02.006 · Cited by 23
Hata, M., Tsujikawa, A., Miyake, M., Yamashiro, K., Ooto, S., Oishi, A., Nakata, I., Takahashi, A., & Yoshimura, N. (2014) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-014-2675-6 · Cited by 23
“In contrast, a number of studies have shown encouraging results of PDT for the treatment of vascular lesions of PCV [7–11].”
BackgroundResultInfluentialSaito, M., Kano, M., Itagaki, K., Ise, S., Imaizumi, K., & Sekiryu, T. (2015) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-015-0411-3 · Cited by 23
Verteporfin Photodynamic Therapy for the Treatment of Chorioretinal Conditions: A Narrative Review
Garg, S. J., & Hadziahmetovic, M. (2024) · Clinical ophthalmology · doi:10.2147/opth.s464371 · Cited by 30
Baek, J., Lee, J. H., Jeon, S., & Lee, W. K. (2018) · Eye · doi:10.1038/s41433-018-0228-7 · Cited by 22
Self-citationPathways of Fluid Leakage in Age-Related Macular Degeneration
Fouad, Y. A., Santina, A., Bousquet, E., Sadda, S. R., & Sarraf, D. (2023) · Retina · doi:10.1097/iae.0000000000003798 · Cited by 23
Ibrahim, F. N. I. M., Teo, K. Y. C., Tan, T., Chan, H. H., Chandrasekaran, P. R., Lee, S., Tan, A. C. S., Mathur, R., Chan, C. M., Sim, S. S., et al. (2024) · Frontiers in Ophthalmology · doi:10.3389/fopht.2023.1346322 · Cited by 24
Honda, S., Miki, A., Yanagisawa, S., Matsumiya, W., Nagai, T., & Tsukahara, Y. (2014) · Ophthalmologica · doi:10.1159/000360308 · Cited by 22
Hikichi, T., Higuchi, M., Matsushita, T., Kosaka, S., Matsushita, R., Takami, K., & Ohtsuka, H. (2013) · Retina · doi:10.1097/iae.0b013e31828bcafa · Cited by 22
Ho, M., Lo, E. C.-F., Young, A. L., & Liu, D. T. L. (2014) · Eye · doi:10.1038/eye.2014.222 · Cited by 22
Hu, J., Leng, X., Hu, Y., Atik, A., Song, X., Li, Z., Liu, Y., & Lü, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147346 · Cited by 23
Kim, J. M., Kang, S. W., Son, D. Y., & Bae, K. (2017) · Retina · doi:10.1097/iae.0000000000001435 · Cited by 25
Prognostic factors of 2-year outcomes of ranibizumab therapy for polypoidal choroidal vasculopathy
Hikichi, T., Kitamei, H., & Shioya, S. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305606 · Cited by 22
Todorich, B., Thanos, A., Yonekawa, Y., Mane, G., Hasbrook, M., Thomas, B. J., Woodward, M. A., Williams, G. A., Capone, A., Wolfe, J. D., et al. (2017) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126416683299 · Cited by 23
Suzuki, M., Nagai, N., Shinoda, H., Uchida, A., Kurihara, T., Tomita, Y., Kamoshita, M., Iyama, C., Tsubota, K., & Ozawa, Y. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.03.024 · Cited by 20
CRISPR Technology for Ocular Angiogenesis
Chung, S. H., Sin, T.-N., Ngo, T., & Yiu, G. C. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.594984 · Cited by 21
Matsumiya, W., Honda, S., Otsuka, K., Miki, A., Nagai, T., Imai, H., Kusuhara, S., & Nakamura, M. (2016) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-016-3500-1 · Cited by 22
“The regression rates at 3 and 12months were comparable to that of IVR+vPDT combination therapy described in the EVERESTstudy andmay be superior to those of IVA monotherapy described in previous reports [9, 12, 15].”
BackgroundResultInfluentialTakahashi, K. A., Ohji, M., Terasaki, H., Honda, S., Margaron, P., Guerin, T., & Yuzawa, M. (2018) · Clinical ophthalmology · doi:10.2147/opth.s171015 · Cited by 20
“The Central Reading Center (Fundus Image Reading Centre, Singapore) confirmed the presence of PCV in one study eye and eligibility for enrolment,(21) using a standardized reading protocol using well-defined grading criteria as the EVEREST study.(20) The BCVA letter score range needed for eligibility was between 78 and…”
Ranibizumab non-response in pachychoroid neovasculopathy: Effects of switching to aflibercept
Schworm, B., Luft, N., Keidel, L. F., Herold, T., Wolf, A., Priglinger, S. G., & Siedlecki, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-65370-w · Cited by 21
Ogino, K., Tsujikawa, A., Yamashiro, K., Ooto, S., Oishi, A., Nakata, I., Miyake, M., & Yoshimura, N. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-11494 · Cited by 20
“2 letters after 6 months of IVR treatment.(8) Another recent investigation by Matsumiya et al.”
BackgroundKim, J. H., Chang, Y. S., Kim, J. W., Kim, C. G., Lee, D. W., & Kim, Y. J. (2017) · Retina · doi:10.1097/iae.0000000000001845 · Cited by 19
Nesper, P. L., Ong, J. X., & Fawzi, A. A. (2021) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.62.3.12 · Cited by 19
ADJUSTED RETREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY AFTER COMBINATION THERAPY
Jeon, S., Lee, W. K., & Kim, K. S. (2013) · Retina · doi:10.1097/iae.0b013e318276e096 · Cited by 19
“Nevertheless, patients given ranibizumab monotherapy gained significant improvement in VA at 6 months, despite persistence of polyps, perhaps because of strong anti-leakage drug effect.(26) Although continuous injections were required in most patients, such findings do suggest that anti-VEGF agents may successfully co…”
BackgroundSelf-citationNakata, I., Tsujikawa, A., Yamashiro, K., Otani, A., Ooto, S., Akagi-Kurashige, Y., Ueda‐Arakawa, N., Iwama, D., & Yoshimura, N. (2012) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-012-2137-y · Cited by 19
Takayama, K., Kaneko, H., Kataoka, K., Hattori, K., Ra, E., Tsunekawa, T., Fukukita, H., Haga, F., Ito, Y., & Terasaki, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176100 · Cited by 21
Wong, I. Y., Shi, X., Gangwani, R. A., Zhao, P., Iu, L. P. L., Li, Q., Ng, A. L. K., & Li, X. (2015) · BMC Ophthalmology · doi:10.1186/s12886-015-0061-8 · Cited by 19
Kim, H., Lee, S. C., Kim, S. M., Lee, J. H., Koh, H. J., Kim, S. S., Byeon, S. H., Kim, M., & Lee, C. S. (2015) · Ophthalmologica · doi:10.1159/000380830 · Cited by 18
Self-citationSakai, T., Okano, K., Kohno, H., & Tsuneoka, H. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13130 · Cited by 20
Metadata
- Authors
- Koh, A., Lee, W. K., Chen, L.-J., Chen, S.-J., Hashad, Y., Kim, H., Lai, T. Y., Pilz, S., Ruamviboonsuk, P., Tokaji, E., Weisberger, A., & Lim, T. H.
- Affiliations
- Eye & Retina Surgeons (SG)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Mackay Memorial Hospital (TW)
- Taipei Veterans General Hospital (TW)
- National Yang Ming University (TW)
- Corresponding author
- Koh, Adrian
- Hashad, Yehia
- Weisberger, Annemarie
- ORCID
- Venue
- Retina
- Published
- 2012-09
- Volume
- 32
- Issue
- 8
- Pages
- 1453-1464
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W1976433015
- Cited by
- 587
- References
- 30
- Citations by year
- 2026: 21 · 2025: 39 · 2024: 32 · 2023: 20 · 2022: 31 · 2021: 54 · 2020: 46 · 2019: 40 · 2018: 50 · 2017: 63 · 2016: 52 · 2015: 51 · 2014: 39 · 2013: 41 · 2012: 8
- FWCI
- 41.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Retina (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
- Keywords
- verteporfin photodynamic therapy, ranibizumab, combination therapy, polyp regression, best-corrected visual acuity, anti-VEGF therapy, EVEREST trial
- MeSH terms
- Ranibizumab, Verteporfin, Aged, Choroid, Combined Modality Therapy, Double-Blind Method, Coloring Agents, Female, Fluorescein Angiography, Humans, Indocyanine Green, Male, Middle Aged, Photochemotherapy, Polyps, Porphyrins, Visual Acuity, Choroid Diseases, Treatment Outcome, Photosensitizing Agents, Angiogenesis Inhibitors, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.